Evidence map›Paper›PMID 41745725›Full record

Trial reportToxins2026

From Bite to Recovery: Safety and Efficacy of Pan-African Polyvalent Antivenom Used for Treating Snakebites in Cameroon.

Tatiana K Djikeussi, Vishwas Sovani, Rogacien Kana, Lorraine G Nekame, Awelsa Benoit, Malama Toussaint, Louabalbe P Emmanuel, Ngu Hilmann, Baba Souley, Issaka Sali and 10 more

Abstract readMulticenter StudyClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tatiana K DjikeussiDepartment of Immunology and Parasitology, Faculty of Health Sciences, University of Buea, Buea, Cameroon.ORCID 0009-0001-9634-8532
Vishwas SovaniPharmawisdom, Thane 400604, India.ORCID 0000-0002-2829-320X
Rogacien KanaHealth for Africa Now, Douala, Cameroon.ORCID 0009-0006-9009-0880
Lorraine G NekameHealth for Africa Now, Douala, Cameroon.
Awelsa BenoitDistrict Hospital, Mayo Oulo, Cameroon.
Malama ToussaintDistrict Hospital, Mayo Oulo, Cameroon.
Louabalbe P EmmanuelDistrict Hospital, Poli, Cameroon.
Ngu HilmannDistrict Hospital, Poli, Cameroon.
Baba SouleyDistrict Hospital, Mayo Oulo, Cameroon.
Issaka SaliRegional Hospital, Garoua, Cameroon.
Yaouba DaoaudaRegional Hospital, Garoua, Cameroon.
Balkissou A DodoRegional Hospital, Garoua, Cameroon.
Armelle MessaDistrict Hospital, Gashiga, Cameroon.
Maraimou I IssaDistrict Hospital, Gashiga, Cameroon.
Sogueba I MaruisDistrict Hospital, Gashiga, Cameroon.
Arthur Djoumessi2N Pharmaceutique, Douala, Cameroon.ORCID 0000-0003-0416-2747
Nathalie Elombo2N Pharmaceutique, Douala, Cameroon.
Gavli DongoaRegional Delegation of Public Health, Garoua, Cameroon.
Gilbert KeblouabeRegional Delegation of Public Health, Garoua, Cameroon.
Yaoua Z AladjiRegional Delegation of Public Health, Garoua, Cameroon.

Funding

Premium Serums & Vaccines Pvt. Ltd NA
6 · The paper itself

Abstract

Snakebite envenomation (SBE) is a major public health issue in sub-Saharan Africa (SSA), particularly in Cameroon. This Phase IV, multicenter, open-label study was conducted from June 2024 to December 2024 to evaluate the safety and efficacy of PANAF-Premium™, a World Health Organization (WHO)-approved polyvalent antivenom that was introduced in Cameroon in 2023, given that prospectively gathered data and studies on this antivenom's safety in SSA are limited. In total, 130 victims admitted to four district hospitals in North Cameroon with confirmed SBE were included. Data on envenomation syndromes, clinical outcomes, adverse events, and treatment response were recorded.

Indexed as

AntiveninsSnake BitesAdolescentAdultAgedAnimalsCameroonChildChild, PreschoolEchisFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultAntiveninsantivenom safetyCameroonPANAF-Premium™Phase IV study/post-marketing surveillancesnakebite envenomation

Identifiers

PMID41745725
PMCPMC12944739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.